{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:59:25Z","timestamp":1790362765687,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03171-3","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:30:57Z","timestamp":1786707057000},"page":"2114-2125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Ryoichi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"3171_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888","journal-title":"N Engl J Med"},{"key":"3171_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778\u20131789","journal-title":"N Engl J Med"},{"key":"3171_CR4","doi-asserted-by":"publisher","first-page":"104506","DOI":"10.1016\/j.esmoop.2025.104506","volume":"10","author":"S Gupta","year":"2025","unstructured":"Gupta S, Climent Duran MA, Sridhar SS et al (2025) Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients. ESMO Open 10:104506","journal-title":"ESMO Open"},{"key":"3171_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn NE, Zhang W, Belk JA et al (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185:1924-1942 e1923","journal-title":"Cell"},{"key":"3171_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137\u2013148","journal-title":"Immunity"},{"key":"3171_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10147-023-02421-y","volume":"28","author":"T Sano","year":"2023","unstructured":"Sano T, Saito R, Aizawa R et al (2023) Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma. Int J Clin Oncol 28:1573\u20131584","journal-title":"Int J Clin Oncol"},{"key":"3171_CR8","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41467-025-57009-z","volume":"16","author":"S Goswami","year":"2025","unstructured":"Goswami S, Gao J, Basu S et al (2025) Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun 16:1846","journal-title":"Nat Commun"},{"key":"3171_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.eururo.2023.05.005","volume":"84","author":"A Bamias","year":"2023","unstructured":"Bamias A, Stenzl A, Brown SL et al (2023) Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European association of urology, European society for radiotherapy and oncology, and European society of medical oncology genitourinary faculty. Eur Urol 84:381\u2013389","journal-title":"Eur Urol"},{"key":"3171_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/0090-4295(82)90462-9","volume":"20","author":"RS Cowles","year":"1982","unstructured":"Cowles RS, Johnson DE, McMurtrey MJ (1982) Long-term results following thoracotomy for metastatic bladder cancer. Urology 20:390\u2013392","journal-title":"Urology"},{"key":"3171_CR11","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","volume":"17","author":"PM Dodd","year":"1999","unstructured":"Dodd PM, McCaffrey JA, Herr H et al (1999) Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17:2546\u20132552","journal-title":"J Clin Oncol"},{"key":"3171_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0090-4295(00)00867-0","volume":"57","author":"T Otto","year":"2001","unstructured":"Otto T, Krege S, Suhr J et al (2001) Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57:55\u201359","journal-title":"Urology"},{"key":"3171_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1097\/01.ju.0000067601.29966.4a","volume":"169","author":"P Sweeney","year":"2003","unstructured":"Sweeney P, Millikan R, Donat M et al (2003) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113\u20132117","journal-title":"J Urol"},{"key":"3171_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","volume":"171","author":"AO Siefker-Radtke","year":"2004","unstructured":"Siefker-Radtke AO, Walsh GL, Pisters LL et al (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171:145\u2013148","journal-title":"J Urol"},{"key":"3171_CR15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","volume":"55","author":"J Lehmann","year":"2009","unstructured":"Lehmann J, Suttmann H, Albers P et al (2009) Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30\/05). Eur Urol 55:1293\u20131299","journal-title":"Eur Urol"},{"key":"3171_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1510\/icvts.2010.236687","volume":"11","author":"R Kanzaki","year":"2010","unstructured":"Kanzaki R, Higashiyama M, Fujiwara A et al (2010) Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact Cardiovasc Thorac Surg 11:60\u201364","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"3171_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.athoracsur.2011.03.097","volume":"92","author":"H Matsuguma","year":"2011","unstructured":"Matsuguma H, Yoshino I, Ito H et al (2011) Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg 92:449\u2013453","journal-title":"Ann Thorac Surg"},{"key":"3171_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5090\/kjtcs.2012.45.4.242","volume":"45","author":"WS Han","year":"2012","unstructured":"Han WS, Kim K, Park JS (2012) Result of surgical resection for pulmonary metastasis from urothelial carcinoma. Korean J Thorac Cardiovasc Surg 45:242\u2013245","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"3171_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10147-011-0350-z","volume":"18","author":"K Bekku","year":"2013","unstructured":"Bekku K, Saika T, Kobayashi Y et al (2013) Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Int J Clin Oncol 18:110\u2013115","journal-title":"Int J Clin Oncol"},{"key":"3171_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","volume":"191","author":"T Abe","year":"2014","unstructured":"Abe T, Kitamura H, Obara W et al (2014) Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan. J Urol 191:932\u2013936","journal-title":"J Urol"},{"key":"3171_CR21","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/j.clgc.2015.04.013","volume":"13","author":"T Kim","year":"2015","unstructured":"Kim T, Ahn JH, You D et al (2015) Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer. Clin Genitourin Cancer 13:e297\u2013e304","journal-title":"Clin Genitourin Cancer"},{"key":"3171_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clgc.2014.06.003","volume":"13","author":"A Necchi","year":"2015","unstructured":"Necchi A, Giannatempo P, Lo Vullo S et al (2015) Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design. Clin Genitourin Cancer 13:80-86 e81","journal-title":"Clin Genitourin Cancer"},{"key":"3171_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1055\/s-0036-1583271","volume":"65","author":"L Luzzi","year":"2017","unstructured":"Luzzi L, Marulli G, Solli P et al (2017) Long-term results and prognostic factors of pulmonary metastasectomy in patients with metastatic transitional cell carcinoma. Thorac Cardiovasc Surg 65:567\u2013571","journal-title":"Thorac Cardiovasc Surg"},{"key":"3171_CR24","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1245\/s10434-017-5970-8","volume":"24","author":"T Nakagawa","year":"2017","unstructured":"Nakagawa T, Taguchi S, Kanatani A et al (2017) Oncologic outcome of metastasectomy for urothelial carcinoma: who is the best candidate? Ann Surg Oncol 24:2794\u20132800","journal-title":"Ann Surg Oncol"},{"key":"3171_CR25","doi-asserted-by":"publisher","first-page":"9 e11","DOI":"10.1016\/j.urolonc.2017.09.009","volume":"36","author":"BM Faltas","year":"2018","unstructured":"Faltas BM, Gennarelli RL, Elkin E et al (2018) Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes. Urol Oncol 36:9 e11-19 e17","journal-title":"Urol Oncol"},{"key":"3171_CR26","doi-asserted-by":"publisher","first-page":"61 e21","DOI":"10.1016\/j.urolonc.2021.07.015","volume":"40","author":"F Dursun","year":"2022","unstructured":"Dursun F, Mackay A, Guzman JCA et al (2022) Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: an analysis of the national cancer database. Urol Oncol 40:61 e21-61 e28","journal-title":"Urol Oncol"},{"key":"3171_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","volume":"73","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Dalbagni G, Daneshmand S et al (2018) The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol 73:543\u2013557","journal-title":"Eur Urol"},{"key":"3171_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.euf.2022.11.020","volume":"9","author":"M Abufaraj","year":"2023","unstructured":"Abufaraj M, Li R, Meeks J et al (2023) Cytoreductive surgery in patients with urothelial bladder cancer. Eur Urol Focus 9:278\u2013279","journal-title":"Eur Urol Focus"},{"key":"3171_CR29","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/j.clgc.2020.01.003","volume":"18","author":"E Lemke","year":"2020","unstructured":"Lemke E, Sahasrabudhe D, Guancial E et al (2020) The role of metastasectomy in urothelial carcinoma: where are we in 2020? Clin Genitourin Cancer 18:e478\u2013e483","journal-title":"Clin Genitourin Cancer"},{"key":"3171_CR30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.21037\/tau-19-624","volume":"9","author":"T Muilwijk","year":"2020","unstructured":"Muilwijk T, Akand M, Van der Aa F et al (2020) Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol 9:1296\u20131305","journal-title":"Transl Androl Urol"},{"key":"3171_CR31","doi-asserted-by":"publisher","first-page":"175883592110473","DOI":"10.1177\/17588359211047352","volume":"13","author":"C Stecca","year":"2021","unstructured":"Stecca C, Abdeljalil O, Sridhar SS (2021) Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol 13:17588359211047352","journal-title":"Ther Adv Med Oncol"},{"key":"3171_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183201","author":"A Angrisani","year":"2024","unstructured":"Angrisani A, Bosetti DG, Vogl UM et al (2024) Oligometastatic urothelial cancer and stereotactic body radiotherapy: a systematic review and an updated insight of current evidence and future directions. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16183201","journal-title":"Cancers (Basel)"},{"key":"3171_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00345-023-04744-x","volume":"42","author":"S Ashley","year":"2024","unstructured":"Ashley S, Choudhury A, Hoskin P et al (2024) Radiotherapy in metastatic bladder cancer. World J Urol 42:47","journal-title":"World J Urol"},{"key":"3171_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","volume":"33","author":"C Franzese","year":"2021","unstructured":"Franzese C, Francolini G, Nicosia L et al (2021) Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol (R Coll Radiol) 33:50\u201356","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3171_CR35","first-page":"100124","volume":"19","author":"G Francolini","year":"2019","unstructured":"Francolini G, Desideri I, Detti B et al (2019) Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun 19:100124","journal-title":"Cancer Treat Res Commun"},{"key":"3171_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13014-024-02465-y","volume":"19","author":"FC Svedman","year":"2024","unstructured":"Svedman FC, Holmsten K, Jawdat F et al (2024) Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience. Radiat Oncol 19:74","journal-title":"Radiat Oncol"},{"key":"3171_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.euf.2025.03.011","volume":"11","author":"M Miszczyk","year":"2025","unstructured":"Miszczyk M, Bilski M, Koi T et al (2025) Metastasis-directed therapy in the management of urothelial carcinoma: a systematic review and meta-analysis. Eur Urol Focus 11:638\u2013647","journal-title":"Eur Urol Focus"},{"key":"3171_CR38","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","volume":"39","author":"M Daro-Faye","year":"2021","unstructured":"Daro-Faye M, Kassouf W, Souhami L et al (2021) Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 39:1331\u20131343","journal-title":"World J Urol"},{"key":"3171_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K et al (2019) Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 75:707\u2013711","journal-title":"Eur Urol"},{"key":"3171_CR40","doi-asserted-by":"publisher","first-page":"19802","DOI":"10.1038\/s41598-024-70182-3","volume":"14","author":"M Rizzo","year":"2024","unstructured":"Rizzo M, Soares A, Grande E et al (2024) Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Sci Rep 14:19802","journal-title":"Sci Rep"},{"key":"3171_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041161","author":"A Aboudaram","year":"2023","unstructured":"Aboudaram A, Chaltiel L, Pouessel D et al (2023) Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15041161","journal-title":"Cancers (Basel)"},{"key":"3171_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyz197","volume":"50","author":"T Abe","year":"2020","unstructured":"Abe T, Minami K, Harabayashi T et al (2020) Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol 50:206\u2013213","journal-title":"Jpn J Clin Oncol"},{"key":"3171_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/MOU.0000000000000329","volume":"26","author":"T Abe","year":"2016","unstructured":"Abe T, Matsumoto R, Shinohara N (2016) Role of surgical consolidation in metastatic urothelial carcinoma. Curr Opin Urol 26:573\u2013580","journal-title":"Curr Opin Urol"},{"key":"3171_CR44","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.21037\/tau.2017.08.09","volume":"6","author":"K Decaestecker","year":"2017","unstructured":"Decaestecker K, Fonteyne V, Oosterlinck W (2017) Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder. Transl Androl Urol 6:1117\u20131122","journal-title":"Transl Androl Urol"},{"key":"3171_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","volume":"3","author":"M Moschini","year":"2020","unstructured":"Moschini M, Xylinas E, Zamboni S et al (2020) Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database. Eur Urol Oncol 3:94\u2013101","journal-title":"Eur Urol Oncol"},{"key":"3171_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/BLC-170130","volume":"4","author":"R Li","year":"2018","unstructured":"Li R, Metcalfe M, Kukreja J et al (2018) Role of radical cystectomy in non-organ confined bladder cancer: a systematic review. Bladder Cancer 4:31\u201340","journal-title":"Bladder Cancer"},{"key":"3171_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canrad.2023.02.004","volume":"28","author":"P Sargos","year":"2024","unstructured":"Sargos P, Le Guevelou J, Khalifa J et al (2024) The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer Radiother 28:56\u201365","journal-title":"Cancer Radiother"},{"key":"3171_CR48","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.21873\/anticanres.16373","volume":"43","author":"T Sano","year":"2023","unstructured":"Sano T, Aizawa R, Ito K et al (2023) Efficacy and tolerability of second-line pembrolizumab with radiation therapy in advanced urothelial carcinoma. Anticancer Res 43:2119\u20132126","journal-title":"Anticancer Res"},{"key":"3171_CR49","doi-asserted-by":"publisher","first-page":"110986","DOI":"10.1016\/j.urolonc.2025.110986","volume":"44","author":"S Bracarda","year":"2026","unstructured":"Bracarda S, Mammone G, Mosillo C et al (2026) Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: moving from risk factors to micrometastatic disease in the perioperative setting. Urol Oncol 44:110986","journal-title":"Urol Oncol"},{"key":"3171_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bju.16836","volume":"136","author":"L Cella","year":"2025","unstructured":"Cella L, Moretto S, Contieri R et al (2025) The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis. BJU Int 136:602\u2013611","journal-title":"BJU Int"},{"key":"3171_CR51","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1002\/cam4.4327","volume":"10","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wang P, Qi K et al (2021) The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma. Cancer Med 10:8079\u20138090","journal-title":"Cancer Med"},{"key":"3171_CR52","doi-asserted-by":"publisher","first-page":"1045831","DOI":"10.3389\/fsurg.2022.1045831","volume":"9","author":"XH Hu","year":"2022","unstructured":"Hu XH, Miao J, Qian L et al (2022) The predictors and surgical outcomes of different distant metastases patterns in upper tract urothelial carcinoma: a SEER-based study. Front Surg 9:1045831","journal-title":"Front Surg"},{"key":"3171_CR53","doi-asserted-by":"publisher","first-page":"903123","DOI":"10.3389\/fsurg.2022.903123","volume":"9","author":"WY Lin","year":"2022","unstructured":"Lin WY, Lin MH, Yang YH et al (2022) Survival impact of nephroureterectomy for de novo stage IV nonmetastatic and metastatic upper tract urothelial carcinoma. Front Surg 9:903123","journal-title":"Front Surg"},{"key":"3171_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","volume":"87","author":"A Masson-Lecomte","year":"2025","unstructured":"Masson-Lecomte A, Birtle A, Pradere B et al (2025) European Association of Urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update. Eur Urol 87:697\u2013716","journal-title":"Eur Urol"},{"key":"3171_CR55","unstructured":"ClinicalTrials.gov Identifier: NCT07413523. Randomized trial of standard of care with or without metastases-directed stereotactic body radiation therapy in patients affected by oligometastatic urothelial carcinoma (ASTRA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT07413523"},{"key":"3171_CR56","unstructured":"Ghali F, Petrylak D, An Y et al (2025) CONSOLIDATE-01: Phase II trial of consolidative surgery following enfortumab vedotin and pembrolizumab in patients with locally advanced\/oligometastatic urothelial carcinoma. Presented at: Society of Urologic Oncology Annual Meeting, Phoenix, AZ. Abstract 47 (ClinicalTrials.gov identifier NCT07048457)"},{"key":"3171_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cancers18020189","volume":"18","author":"M Perera","year":"2026","unstructured":"Perera M et al (2026) Oligometastatic bladder cancer: current definitions, diagnostic challenges, and evolving therapeutic strategies. Cancers (Basel) 18:189","journal-title":"Cancers (Basel)"},{"key":"3171_CR58","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtroder K, Sethi H et al (2019) Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 37:1547\u20131557","journal-title":"J Clin Oncol"},{"key":"3171_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ et al (2022) Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 82:212\u2013222","journal-title":"Eur Urol"},{"key":"3171_CR60","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog SV, Birkenkamp-Demtroder K, Nordentoft I et al (2023) Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clin Cancer Res 29:4797\u20134807","journal-title":"Clin Cancer Res"},{"key":"3171_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","volume":"86","author":"I Nordentoft","year":"2024","unstructured":"Nordentoft I, Lindskrog SV, Birkenkamp-Demtroder K et al (2024) Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma. Eur Urol 86:301\u2013311","journal-title":"Eur Urol"},{"key":"3171_CR62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","volume":"7","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Tillu N, Cumarasamy S et al (2024) Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy. Eur Urol Oncol 7:1105\u20131112","journal-title":"Eur Urol Oncol"},{"key":"3171_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.027","author":"A Eraky","year":"2025","unstructured":"Eraky A, Ben-David R, Hug B et al (2025) Bladder cancer with undetectable circulating tumor DNA after radical cystectomy may be amenable to a less intense imaging surveillance protocol: a diagnostic accuracy study. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.04.027","journal-title":"Eur Urol Oncol"},{"key":"3171_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","author":"T Powles","year":"2025","unstructured":"Powles T, Kann AG, Castellano D et al (2025) ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2511885","journal-title":"N Engl J Med"},{"key":"3171_CR65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","volume":"7","author":"E Crupi","year":"2024","unstructured":"Crupi E, Costa de Padua T, Marandino L et al (2024) Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol 7:44\u201352","journal-title":"Eur Urol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03171-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:02:51Z","timestamp":1790359371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03171-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03171-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest for any of the authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}